Showing 6501-6510 of 8821 results for "".
- Data Suggest Makucell's Asymmtate Reverses Gene Expression in Aging Skinhttps://practicaldermatology.com/news/20120725-makucell_announces_results_on_proprietary_technology_asymmtate/2459765/Makucell, Inc.'s Asymmtate(TM), the key ingredient in the Renewnt line, may reverse gene expression changes associated with aging skin and with lentigines. Findings for Asymmtate, a proprietary cosmetic ingredient that influences the gene co-act
- Alcohol May Influence Skin Cancer Riskhttps://practicaldermatology.com/news/20120720-alcohol_may_influence_skin_cancer_risk/2459766/Evidence suggests that alcohol consumption may have some influence on risk for developing BCC but not SCC. (J Invest Dermatol. E-pub) Consumption of wine and spirits, specifically, appears to increase BCC risk, while beer consumption does not. Results come from an analysis of data on 54,766 people e
- Ellman International Acquires Four Low-cost Lasers from Sandstonehttps://practicaldermatology.com/news/20120720-ellman_international_acquires_four_low-cost_lasers_from_sandstone/2459768/Ellman International, Inc. has acquired the assets of Sandstone Medical Technologies, LLC., a recognized leader in the aesthetic laser and IPL technology field. Sandstone's high quality laser and IPL portfolio offers four multifunctional systems, a
- Pycnogenol Improves Visible Signs of Aginghttps://practicaldermatology.com/news/20120718-pycnogenol_improves_visible_signs_of_aging/2459770/Pycnogenol is effective in improving visible signs of skin aging in women aged 55 to 68 years, according to a study published in a recent issue of Skin Pharmacology and Physiology. The study found that after 12 weeks of supplementing with Pycno
- TriPollar RF Technology Launches for Acne Vulgarishttps://practicaldermatology.com/news/20120712-tripollar_rf_technology_launches_for_acne_vulgaris/2459773/The new Apollo powered by TriPollar utilizes advanced radiofrequency technology—the latest alternative for treating acne, according to the company. A recent study demonstrated that TriPollar technology is
- Ulthera Announces Indication for Decolletage in Asiahttps://practicaldermatology.com/news/20120709-ulthera_announces_indication_for_dcolletage_in_asia/2459776/Ulthera, Inc., a global, growth-stage medical device company, announced the commercial availability of the Ulthera System in select Asian countries to non-invasively treat the skin on the chest area, or décolletage. The Ulthera Sys
- CellCeuticals Nominated for Cosmetic Innovation Awardhttps://practicaldermatology.com/news/20120629-cellceuticals_nominated_for_cosmetic_innovation_award/2459777/CellCeuticals Skin Care, Inc., Biomedical Skin Treatments was named a finalist in two categories by the Independent Cosmetic Manufacturers and Distributors Association (ICMAD). InterActive Moisture Serum 2 was nominated for Best Skin Care P
- Cosmetic Bootcamp Adds Topics to Summer Meetinghttps://practicaldermatology.com/news/20120627-cosmetic_bootcamp_adds_topics_to_summer_meeting/2459778/The Cosmetic Bootcamp, an educational symposium for the core aesthetic specialties, has added topics to its summer sessions. These include Dr. David Sarwer (University of Pennsylvania, a nationally known expert on the psychology of cosmetic pati
- Wellness Center USA Inc. Signs Agreement to Acquire Psoria-Shield Inc.https://practicaldermatology.com/news/20120626-wellness_center_usa_inc_signs_agreement_to_acquire_psoria-shield_inc/2459782/Wellness Center USA Inc.(OTCQB/OTCBB: WCUI), a healthcare and nutraceutical company, signed a share exchange agreement to acquire Psoria-Shield Inc. (PSI), a developer and manufacturer of UV p
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=33